Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Neurology · Episodic Ataxia Type 9

Living with EA9: Progression and Long-Term Outlook

At a Glance

EA9 can cause recurring episodes of poor coordination and a gradual decline in baseline balance, but the pace varies widely. SARA scores help track changes, and genetic counseling can clarify inheritance and family-planning options.

Living with Episodic Ataxia Type 9 (EA9) or its sister condition, SCA27B, means navigating a condition that can change over decades. While the “episodes” are the most visible part of the disease early on, the long-term outlook often involves a slow, gradual shift in baseline coordination [1][2].

Because these conditions are at the forefront of medical research, our understanding of the “long-term” is still growing. Most of what we know comes from the study of FGF14 repeat expansions (SCA27B), which appear to be more common than the specific FGF14 sequence variants (EA9) [3].

Understanding Progression: The SARA Score

Doctors use a tool called the SARA (Scale for the Assessment and Rating of Ataxia) to track how coordination changes over time. The SARA scale ranges from 0 (no ataxia) to 40 (severe ataxia).

In large groups of patients, the progression of FGF14-related ataxia is typically described as “slowly progressive”:

  • The Average Pace: On average, scores increase by about 0.3 to 0.5 points per year in prospective SCA27B cohorts. These figures do not automatically apply to FGF14 sequence variants or SCN2A [2][1]. For context, this means it might take several years for a patient to notice a significant change in their daily walking ability.
  • Variation: Not everyone follows this average. A small subgroup of patients with specific genetic patterns may progress faster, while others remain stable for long periods [1].
  • Mobility Aids: In one study, about 50% of patients began using a “unilateral mobility aid” (like a cane) after living with the condition for approximately eight years in a specific SCA27B cohort [2].

Beyond Balance: The Cognitive and Affective Side

The cerebellum does more than just coordinate movement; it also helps “smooth out” thoughts and emotions. When the cerebellum is affected, some patients experience Cerebellar Cognitive Affective Syndrome (CCAS), also known as Schmahmann’s Syndrome [4][5]. These symptoms are not universally established for all genetic subgroups; assessments should be based on your actual concerns.

Symptoms of CCAS can include:

  • Executive Function: Difficulty with multi-tasking, planning, or organizing complex tasks [4].
  • Social Cognition: Challenges in reading social cues or managing emotional responses [4].
  • Mood Changes: Increased anxiety or a “flattening” of emotional expression [6].

While some studies have found CCAS symptoms in a significant number of patients, others find that cognitive issues remain very mild even late in the disease [4][2]. Regular check-ins with your care team can help you identify these “invisible” symptoms early.

Family Planning and Genetic Counseling

FGF14-related disorders follow an autosomal dominant inheritance pattern. A confirmed heterozygous pathogenic variant generally carries a 50% chance of being passed on, though penetrance varies [7]. However, the inheritance is more complex than a simple “yes or no”:

  • Reduced Penetrance: Not everyone who carries the gene variant will develop symptoms. This is why you may not have any relatives with a known diagnosis, even if the gene has been in the family for generations [8][9].
  • Parent-of-Origin Effects: In some cases, whether the gene was inherited from the mother or the father affects whether the “repeat expansion” grows or shrinks in the next generation [10].
  • Late Onset: Because symptoms often don’t appear until middle age, many people have children before they know they carry the variant [7].

Genetic counseling is highly recommended for anyone with an FGF14 diagnosis to navigate these complexities and discuss reproductive options.

Living with Unpredictability

The “episodic” nature of the disease can create a unique psychological burden. Living with the knowledge that a severe episode could happen at any time—triggered by something as common as a fever or a stressful day—requires resilience.

While the condition is progressive, it is also a journey you can prepare for. By tracking your SARA scores and working with your care team, you can stay informed of the changes, adapt your environment for safety, and continue to prioritize a full life [11][2].

Common questions in this guide

Does EA9 get worse over time?
EA9 may cause a gradual decline in baseline balance and coordination, even when the most noticeable episodes occur earlier in the condition. Progression varies widely, and findings from related SCA27B studies should not be assumed to predict the course of an individual with EA9.
What does a SARA score tell me about EA9?
The SARA, or Scale for the Assessment and Rating of Ataxia, is a clinical tool that rates coordination from 0, meaning no ataxia, to 40, meaning severe ataxia. Repeated scores can help your care team track changes over time, but one score does not determine your complete long-term outlook.
Can EA9 affect thinking, emotions, or social interactions?
Some people with FGF14-related ataxia may experience features of cerebellar cognitive affective syndrome, such as difficulty planning, multitasking, reading social cues, or regulating mood. These changes are not universal and may be mild, so discuss any concerns with your care team.
What is the chance of passing EA9 to a child?
FGF14-related disorders are generally inherited in an autosomal dominant pattern, so a person with a confirmed heterozygous pathogenic variant often has a 50% chance of passing it on in each pregnancy. Reduced penetrance means that not everyone who inherits a variant develops symptoms, so a genetic counselor can explain the risk for your family.
When might I need a cane or another mobility aid?
There is no single timeline for starting a cane or other mobility aid. Your clinician can consider balance, falls, walking safety, and your daily activities; using an aid may be appropriate before a major loss of independence occurs. Progression data from a specific SCA27B group should not be used as a personal prediction for EA9.

Get notified when new evidence is published on episodic ataxia, type 9.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients.

    Traschütz A, Hilgers RD, Erdlenbruch F, et al.

    EBioMedicine 2026; (131()):106437 doi:10.1016/j.ebiom.2026.106437.

    PMID: 42603514
  2. 2

    GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response.

    Wilke C, Pellerin D, Mengel D, et al.

    Brain : a journal of neurology 2023; (146(10)):4144-4157 doi:10.1093/brain/awad157.

    PMID: 37165652
  3. 3

    Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions.

    Mohren L, Erdlenbruch F, Leitão E, et al.

    Nature communications 2024; (15(1)):7665 doi:10.1038/s41467-024-52148-1.

    PMID: 39227614
  4. 4

    Cerebellar cognitive affective syndrome (CCAS) and [18F]-FDG PET findings in spinocerebellar ataxia type SCA27B.

    Cros L, Pellerin D, Palpacuer T, et al.

    Journal of neurology 2026; (273(8)).

    PMID: 42481725
  5. 5

    Phenotype and Genetics of Spinocerebellar Ataxia Type 27B: Novel Movement-disorder Features, Cognitive Impairment, and Repeat Expansion Findings.

    Rashedi R, Peemöller F, Erdmann H, et al.

    Cerebellum (London, England) 2026; (25(4)).

    PMID: 42371259
  6. 6

    Prevalence, Severity, and Progression of Cerebellar Cognitive-Affective Syndrome in Patients With Spinocerebellar Ataxias.

    Petit E, López Domínguez D, Marelli C, et al.

    Neurology 2025; (105(5)):e213980 doi:10.1212/WNL.0000000000213980.

    PMID: 40834346
  7. 7

    Pearls & Oy-sters: SCA27B as an Elusive Genetic Cause of Episodic Neurologic Symptoms in Later Adulthood.

    Yomtoob J, Morse L, Keller Sarmiento IJ, et al.

    Neurology 2026; (106(6)):e214754 doi:10.1212/WNL.0000000000214754.

    PMID: 41698164
  8. 8

    Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

    Chukwuocha I, Pellerin D, Shanmugarajah P, et al.

    Journal of neurology 2025; (272(10)):681 doi:10.1007/s00415-025-13422-4.

    PMID: 41065930
  9. 9

    Spinocerebellar Ataxia Type 27B can be Suspected Based on Clinical Phenotype: The Massachusetts General Hospital Ataxia Center Experience.

    Rettenmaier LA, Chen JYH, MacMore J, et al.

    Cerebellum (London, England) 2025; (24(5)):133 doi:10.1007/s12311-025-01882-3.

    PMID: 40679574
  10. 10

    Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions.

    Méreaux JL, Davoine CS, Pellerin D, et al.

    EBioMedicine 2024; (99()):104931 doi:10.1016/j.ebiom.2023.104931.

    PMID: 38150853
  11. 11

    Goal-Directed Rehabilitation Versus Standard Care for Individuals with Hereditary Cerebellar Ataxia: A Multicenter, Single-Blind, Randomized Controlled Superiority Trial.

    Milne SC, Roberts M, Williams S, et al.

    Annals of neurology 2025; (97(3)):409-424 doi:10.1002/ana.27130.

    PMID: 39520242

This page provides general information about EA9 progression, cognitive changes, and family planning; it is not medical advice. Your neurologist and genetic counselor can interpret your SARA score, genetic findings, and personal outlook.